CPSE:DEMANT
CPSE:DEMANTMedical Equipment

Assessing Demant (CPSE:DEMANT) Valuation As AI-Focused Hearing Devices Draw Fresh Investor Interest

Recent coverage around Demant (CPSE:DEMANT) has centered on its push into AI-powered, lifestyle-focused hearing devices and a broad footprint across hearing aids, diagnostics, and audio communications, which appears to be supporting current investor interest. See our latest analysis for Demant. At a share price of DKK 223.8, Demant has seen short term momentum pick up, with a 1 month share price return of 3.4% and a year to date share price gain of 4.9%. However, the 1 year total shareholder...
CPSE:VWS
CPSE:VWSElectrical

Vestas Wind Systems (CPSE:VWS) Is Up 8.0% After Global Multi-Gigawatt Wind And Service Wins – Has The Bull Case Changed?

In late 2025, Vestas announced a wave of new wind turbine orders totaling several gigawatts across Europe, North America, Asia, and Australia, including its first offshore contract in South Korea and multiple long-term service agreements extending up to 30 years. This broad mix of onshore and offshore projects, spread across developed and emerging wind markets, highlights how Vestas is deepening its global footprint while locking in recurring service revenue over the long term. We’ll now...
CPSE:COLO B
CPSE:COLO BMedical Equipment

The Bull Case For Coloplast (CPSE:COLO B) Could Change Following Executive Team Shake-Up In Key Divisions

Coloplast has recently announced upcoming changes to its Executive Leadership Team, with long-serving leaders in People & Culture and Interventional Urology set to depart and successors, including incoming Interventional Urology head Kevin Hardage from Teleflex, lined up to ensure business continuity. These leadership shifts, particularly in the Interventional Urology division and the global People & Culture function, could influence how effectively Coloplast executes its reorganisation,...
CPSE:FLS
CPSE:FLSMachinery

Broker Upgrade On Turnaround Progress Could Be A Game Changer For FLSmidth (CPSE:FLS)

Earlier this week, Danish engineering group FLSmidth was upgraded from "hold" to "buy" by ABG Sundal Collier, with the broker citing expectations of stronger financials, margin expansion and support from higher metal prices as the company exits a major restructuring phase under departing CEO Mikko Keto. The upgrade underscores how FLSmidth’s completed turnaround and exposure to improving metals markets are reshaping expectations for its order pipeline and profitability profile. We’ll now...
CPSE:ZEAL
CPSE:ZEALBiotechs

Zealand Pharma (CPSE:ZEAL) Valuation After Metabolic Frontier 2030 Roadmap and New OTR Obesity Partnership

Zealand Pharma (CPSE:ZEAL) just doubled down on its obesity and metabolic health ambitions by unveiling its Metabolic Frontier 2030 roadmap alongside a new multi program collaboration with OTR Therapeutics on next generation metabolic drugs. See our latest analysis for Zealand Pharma. Those moves land against a backdrop where the share price has climbed roughly 25% over the last three months but still sits well below earlier levels, and the three year total shareholder return above 150%...
CPSE:STG
CPSE:STGTobacco

Will XQS Pouches and Signature Action Growth Change Scandinavian Tobacco Group's (CPSE:STG) Narrative

In recent months, Scandinavian Tobacco Group reported that its Signature Action cigarillo brand has almost doubled sales, added a new Signature Action Mix variant, and introduced larger 17-pack formats to appeal to value-focused smokers. The company has also moved into the nicotine pouch market with its XQS brand, which has quickly become the sixth-largest pouch label, signalling a meaningful broadening of its product portfolio beyond traditional tobacco. Next, we’ll examine how the rapid...
CPSE:ALK B
CPSE:ALK BPharmaceuticals

How ALK-Abelló’s New North America Commercial Chief Will Impact ALK-Abelló (CPSE:ALK B) Investors

ALK-Abelló has announced that Edward Jordan, a biopharmaceutical executive with more than 30 years of experience, will become Executive Vice President and head of Commercial Operations in North America from January 2026, following the earlier elevation of the region into the Executive Leadership Team to support the Allergy+ strategy. By bringing in a leader with deep allergy and immunology expertise and a history of building US therapeutic markets, ALK-Abelló is clearly prioritizing stronger...